Lake Zurich-based Fresenius Kabi Thursday announced the immediate availability in the U.S. of Stimufend, a drug similar to Neulasta, for use in patients at risk for febrile neutropenia, a common side effect of many anti-cancer medications.
Related posts
-
Schaumburg police looking for woman who attempted to lure children into her car
Schaumburg police are searching for a woman wanted for attempting to lure two children into her... -
State legislators say they will ‘untie the hands’ of Mundelein officials for Ivanhoe Village school impact
Mundelein-area school districts again are urging officials to slow the process involving the proposed Ivanhoe Village... -
State legislators say they will ‘untie the hands’ of Mundelein officials for Ivanhoe Village school impact
Mundelein-area school districts again are urging officials to slow the process involving the proposed Ivanhoe Village...